SpectraScience, Inc. (OTCQB: SCIE) develops and markets a technology platform to determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy. It offers WavSTAT4 Optical Biopsy System, a minimally invasive technology system that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. SNNLive caught up with Michael Oliver, President and CEO of SpectraScience, Inc. at the Healthcare Media Day 2015 in San Francisco, CA.
In this SNNLive Update, our host and Mr. Oliver discuss a couple topics. Mr. Oliver starts off with an overview of SpectraScience, where he discusses the company’s development of an optical biopsy medical technology platform with an initial indication as a diagnostic screener for colorectal cancer. Next, he goes into who is the company’s competition in the space - who else is claiming to be creating diagnostics using optical biopsy technology and how is SpectraScience is different from it’s competitors.
He concludes by discussing the company’s plan for 2015-2016. For more information, check out the website: www.SpectraScience.com
© 2017 Stock News Now
Supported by Superior Web Solutions